1. Home
  2. ALT vs ARDC Comparison

ALT vs ARDC Comparison

Compare ALT & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ARDC
  • Stock Information
  • Founded
  • ALT 1997
  • ARDC 2012
  • Country
  • ALT United States
  • ARDC United States
  • Employees
  • ALT N/A
  • ARDC N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ARDC Investment Managers
  • Sector
  • ALT Health Care
  • ARDC Finance
  • Exchange
  • ALT Nasdaq
  • ARDC Nasdaq
  • Market Cap
  • ALT 292.0M
  • ARDC 344.2M
  • IPO Year
  • ALT N/A
  • ARDC N/A
  • Fundamental
  • Price
  • ALT $3.83
  • ARDC $14.71
  • Analyst Decision
  • ALT Strong Buy
  • ARDC
  • Analyst Count
  • ALT 6
  • ARDC 0
  • Target Price
  • ALT $17.40
  • ARDC N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • ARDC 115.8K
  • Earning Date
  • ALT 08-12-2025
  • ARDC 01-01-0001
  • Dividend Yield
  • ALT N/A
  • ARDC 9.84%
  • EPS Growth
  • ALT N/A
  • ARDC N/A
  • EPS
  • ALT N/A
  • ARDC N/A
  • Revenue
  • ALT $20,000.00
  • ARDC N/A
  • Revenue This Year
  • ALT N/A
  • ARDC N/A
  • Revenue Next Year
  • ALT $761,880.20
  • ARDC N/A
  • P/E Ratio
  • ALT N/A
  • ARDC N/A
  • Revenue Growth
  • ALT N/A
  • ARDC N/A
  • 52 Week Low
  • ALT $2.90
  • ARDC $11.56
  • 52 Week High
  • ALT $11.16
  • ARDC $14.30
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • ARDC 66.23
  • Support Level
  • ALT $3.35
  • ARDC $14.53
  • Resistance Level
  • ALT $3.66
  • ARDC $14.64
  • Average True Range (ATR)
  • ALT 0.19
  • ARDC 0.10
  • MACD
  • ALT 0.07
  • ARDC 0.00
  • Stochastic Oscillator
  • ALT 86.18
  • ARDC 100.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ARDC Ares Dynamic Credit Allocation Fund Inc.

Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).

Share on Social Networks: